1.	Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase IV, Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
2.	German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase IV Type: Treatment Status: Active Age: Over 55 Sponsor: Other Protocol IDs: GMALL02, NCT00198978
3.	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Phase: Phase IV Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL01, NCT00198991
4.	Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults Phase: Phase IV Type: Treatment Status: Active Age: Over 15 Sponsor: Other Protocol IDs: GMALL05, NCT00199082
5.	Efficacy of G-CSF-Priming in Elderly AML Patients Phase: Phase IV Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
6.	Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation Phase: Phase IV Type: Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Plerixafor-UF01, NCT01339572
7.	Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS Phase: Phase IV Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: LAL-AR/2011, NCT01540812
8.	Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Phase: Phase IV Type: Supportive care, Treatment Status: Approved-not yet active Age: 20 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-91, NCT01571518
9.	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZ_L_06003, U1111-1123-9025, NCT01649635
10.	Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes Phase: Phase IV Type: Treatment Status: Active Age: 10 to 90 Sponsor: Other Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985
11.	Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
12.	Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 16 to 80 Sponsor: Other Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
13.	Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 15 to 65 Sponsor: NCI, Other Protocol IDs: CDR0000065658, SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, LY11, NCT00004031
14.	Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CKTO-2000-06, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
15.	Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 20 at diagnosis Sponsor: Other Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719
16.	Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: MCL2004-2, NCT00209222
17.	Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: CDR0000459796, DSHNHL-2004-3, EUDRACT-2005-005218-19, EU-205111, NCT00278408
18.	Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
19.	Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 15 to 70 Sponsor: Other Protocol IDs: CDR0000531125, EORTC-20051, GELA-H10, IIL-EORTC-20051, EUDRACT-2005-002765-37, EU-20657, NCT00433433
20.	Timed-Sequential Induction in CBF-AML Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: P060504, NCT00428558
21.	Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Phase: Phase III Type: Treatment Status: Active Age: 10 and under Sponsor: NCI, Other Protocol IDs: CDR0000573987, COG-ARET0321, ARET0321, NCT00554788
22.	Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: MC0681, P30CA015083, 07-000789, MAYO-MC0681, NCT00566228
23.	Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under at the time of definitive surgery Sponsor: NCI, Other Protocol IDs: CDR0000592812, COG-ACNS0333, ACNS0333, NCT00653068
24.	Alemtuzumab and CHOP in T-cell Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2006-006130-17, NCT00646854
25.	Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-2007-006064-30, 2007-006064-30, CRUK-07/146, NCT00678327